Literature DB >> 29198539

Long-Term Outcomes of Hyperglycemic Preterm Infants Randomized to Tight Glycemic Control.

Anna Catherine Tottman1, Jane Marie Alsweiler2, Frank Harry Bloomfield1, Greg Gamble1, Yannan Jiang1, Myra Leung3, Tanya Poppe3, Benjamin Thompson3, Trecia Ann Wouldes4, Jane Elizabeth Harding5.   

Abstract

OBJECTIVE: To determine whether tight glycemic control of neonatal hyperglycemia changes neurodevelopment, growth, and metabolism at school age. STUDY
DESIGN: Children born very low birth weight and randomized as hyperglycemic neonates to a trial of tight vs standard glycemic control were assessed at 7 years corrected age, including Wechsler Intelligence Scale for Children Fourth Edition, Movement Assessment Battery for Children 2, visual and neurologic examinations, growth measures, dual X-ray absorptiometry, and frequently sampled intravenous glucose tolerance test. The primary outcome was survival without neurodevelopmental impairment at age 7 years. Outcomes were compared using linear regression, adjusted for sex, small for gestational age, birth plurality, and the clustering of twins. Data are reported as number (%) or mean (SD).
RESULTS: Of the 88 infants randomized, 11 (13%) had died and 57 (74% of eligible children) were assessed at corrected age 7 years. Survival without neurodevelopmental impairment occurred in 25 of 68 children (37%), with no significant difference between tight (14 of 35; 40%) and standard (11 of 33; 33%) glycemic control groups (P = .60). Children in the tight group were shorter than those in the standard group (121.3 [6.3] cm vs 125.1 [5.4] cm; P < .05), but had similar weight and head circumference. Children in the tight group had greater height-adjusted lean mass (18.7 [0.3] vs 17.6 [0.2] kg; P < .01) and lower fasting glucose concentrations (84.6 [6.30] vs 90.0 [5.6] mg⋅dL-1; P < .05), but no other differences in measures of body composition or insulin-glucose metabolism.
CONCLUSION: Tight glycemic control for neonatal hyperglycemia does not change survival without neurodevelopmental impairment, but reduces height, increases height-adjusted lean mass, and reduces fasting blood glucose concentrations at school age. TRIAL REGISTRATION: ACTRN: 12606000270516.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood glucose; hyperglycemia; insulin; neonate; neurodevelopment

Mesh:

Substances:

Year:  2017        PMID: 29198539     DOI: 10.1016/j.jpeds.2017.09.081

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Long-Term Outcomes after Early Neonatal Hyperglycemia in VLBW Infants: A Systematic Review.

Authors:  Megan E Paulsen; Sarah Jane Brown; Katherine M Satrom; Johannah M Scheurer; Sara E Ramel; Raghavendra B Rao
Journal:  Neonatology       Date:  2021-08-19       Impact factor: 5.106

Review 2.  Cerebral Effects of Neonatal Dysglycemia.

Authors:  Megan E Paulsen; Raghavendra B Rao
Journal:  Clin Perinatol       Date:  2022-04-21       Impact factor: 2.642

Review 3.  Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants.

Authors:  Alfonso Galderisi; Daniele Trevisanuto; Chiara Russo; Rebecka Hall; Matteo Bruschettini
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

4.  Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants.

Authors:  Alfonso Galderisi; Matteo Bruschettini; Chiara Russo; Rebecka Hall; Daniele Trevisanuto
Journal:  Cochrane Database Syst Rev       Date:  2020-12-21

Review 5.  Nutritional Support Strategies for the Preterm Infant in the Neonatal Intensive Care Unit.

Authors:  William W Hay
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2018-10-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.